Silexion Therapeutics CORP 8-K filings

Silexion Therapeutics announced the selection of AMS Advanced Medical Services GmbH as its Contract Research Organization to support upcoming Phase 2/3 clinical trials for its lead candidate, SIL204.

Silexion Therapeutics Corp. presented an updated corporate overview highlighting positive Phase 2 data for its first-generation KRAS-targeting siRNA and plans for a Phase 2/3 trial for its advanced pan-KRAS silencing therapy, SIL204.

Silexion Therapeutics Corp. disclosed significantly increased net losses and cash burn for 2024, alongside recent capital raises and a going concern warning, following multiple reverse share splits.

Silexion Therapeutics increases its authorized share capital from US$20,000 to US$121,500 following shareholder approval at a reconvened extraordinary general meeting.

Silexion Therapeutics announced strong preclinical efficacy for its SIL204 program across multiple KRAS-driven cancers and reported its second-quarter 2025 financial results.

Silexion Therapeutics Corp secured approximately $1.8 million in gross proceeds by inducing existing warrant holders to exercise their warrants at a reduced price, simultaneously issuing new warrants and incurring significant placement agent fees.

Silexion Therapeutics announced new preclinical data showing up to 97% inhibition of cancer cell growth, including efficacy against a previously untested KRAS Q61H mutation, significantly expanding its pan-KRAS potential.

Silexion Therapeutics Corp has enacted a 1-for-15 reverse share split and adjusted its outstanding warrants to comply with Nasdaq's minimum bid price requirement.

Silexion Therapeutics Corp received a Nasdaq notice for failing to meet the minimum bid price requirement and plans a 1-for-15 reverse share split to regain compliance.

Silexion Therapeutics Corp. announced a 1-for-15 reverse share split, effective July 28, 2025, to comply with Nasdaq's minimum bid price requirement and enhance its market position.

Silexion Therapeutics Corp. shareholders approved a 1-for-15 reverse stock split, an increase in the equity incentive plan, and the election of seven directors at its reconvened 2025 annual general meeting after an initial quorum failure.

Silexion Therapeutics announced positive preclinical data for its RNAi therapy SIL204, demonstrating significant efficacy in human lung cancer cell lines and supporting its innovative delivery system, with a Phase 2/3 clinical trial planned for Q2 2026.

Silexion Therapeutics Corp. filed an amendment to its 8-K report, updating the expected timing for its transfer to the Nasdaq Capital Market and its plan to regain minimum bid price compliance through a 1-for-15 reverse share split.

Silexion Therapeutics Corp received a favorable Nasdaq decision, allowing it to remain listed on the Nasdaq Capital Market subject to achieving $2.5 million in shareholders' equity by September 19, 2025, and addressing a potential bid price deficiency.

Silexion Therapeutics Corp has appealed a Nasdaq delisting notice for failing to meet minimum market value requirements, securing a temporary stay and continued trading of its shares and warrants.

Silexion Therapeutics Corp. reported compelling preclinical data for its RNAi therapeutic candidate, SIL204, demonstrating strong efficacy against KRAS-driven pancreatic, colorectal, and lung cancer cell lines.

Silexion Therapeutics Corp. received a delisting notice from Nasdaq due to non-compliance with minimum market value requirements and intends to appeal the decision while seeking a transfer to the Nasdaq Capital Market.

Silexion Therapeutics reports the completion of preclinical studies exploring the potential of SIL204, its next-generation RNAi therapeutic, in colorectal and lung cancer, in addition to pancreatic cancer.

Silexion Therapeutics announces Q1 2025 financial results, highlighting advancements in its SIL204 preclinical pipeline and a strengthened financial position.

Silexion Therapeutics collaborates with Catalent to optimize formulation and clinical manufacturing of its next-generation siRNA candidate, SIL204, targeting KRAS-driven cancers.

Silexion Therapeutics announces an expanded development plan for SIL204, integrating systemic and intratumoral administration for KRAS-driven pancreatic cancer, based on encouraging preclinical results.

Silexion Therapeutics announces its full year 2024 financial results, highlighting preclinical advancements in its SIL204 program and a strengthened financial position following recent funding.

Silexion Therapeutics Corp. settles a $1.25 million convertible promissory note with EarlyBirdCapital, Inc. through a combination of cash payment, share issuance, and potential settlement amount.

Silexion Therapeutics reports that SIL204, administered subcutaneously, demonstrates efficacy in reducing both primary tumors and metastases in orthotopic pancreatic cancer models.

Silexion Therapeutics Corp has entered into an agreement with existing warrant holders to exercise their warrants for $3.3 million in gross proceeds, while issuing new warrants and placement agent warrants.

Silexion Therapeutics announced positive preclinical data for its SIL-204 therapy, showing significant tumor growth reduction in pancreatic cancer models using a systemic administration approach.

Silexion Therapeutics has announced the pricing of a public offering to raise approximately $5 million through the sale of ordinary shares and warrants.

Silexion Therapeutics enhances its financing flexibility with an amendment to its share purchase agreement and announces encouraging preclinical results for its SIL-204 candidate in combination with chemotherapy for pancreatic cancer.

Silexion Therapeutics has released a corporate presentation highlighting the potential of its SIL204 siRNA therapy for treating KRAS-driven cancers, particularly pancreatic cancer, with plans to initiate a Phase 2/3 trial in 2026.

Silexion Therapeutics Corp files updated financial statements to reflect a reverse share split and provides details on its financial condition.